After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit. Kite has agreed to acquire all ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today, I have the pleasure of talking, about cancer with Cindy, who's the Head of Kite. And thank you ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, ...

At the Tandem Meetings 2025, researchers presented a study of scalp cooling in patients undergoing chemotherapy and ASCT.

Some co-authors also disclosed a relationship with OcuCell, as well as Kite/Gilead, Novartis, Oncternal, Astraveus, Garuda Therapeutics, LifeVault Bio, Smart Immune, Tolerance Bio, and TriArm ...

Armant serves on the scientific advisory board for OcuCell, Inc. Ritz receives research funding from Kite/Gilead, Novartis and Oncternal and serves on Scientific Advisory Boards for Astraveus ...